

Please type a plus sign (+) inside this box →



PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known			
		Application Number	10/049,868		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	February 11, 2002		
		First Named Inventor	Hans Deckmyn and Nancy Cauwenberghs		
		Group Art Unit			
		Examiner Name			
Sheet	2	of	2	Attorney Docket Number	522-1778

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Reverter, "Inhibition of Platelet - mediated, Tissue Factor induced...", J. Clin. Invest, vol a8, no. 3, 8/96, pp 863-874	
		Pareti, "Interaction of porcine von Willebrand factor with the platelet....", British J. of Haematology, vol 82, 1992, pp 81 - 86	
		Becker, "Effects of an Antiplatelet Glycoprotein Ib Antibody on...", Blood, vol 74, no.2, 8/1/89, pp 690-694	
		Ward, "Epitope and functional characterization of the CD42...", Platelet antigens, pp 1336-1337	
		Cowenberghs, "Antithrombotic Effect of Platelet Glycoprotein Ib- Blocking...", Arteriosclerosis, Thrombosis and Vascular Biology,	
		Coller, "A Murine Monoclonal Antibody that Completely Blocks...", J. Clin. Invest. vol 72, 7/83, pp 325-338	
		Shetler, " Antithrombotic Assessment of the Effects of Combination...", 1996, American Heart Association, pp 1719 - 1725	
		Simoons, "Randomized Trial of a GPIIb/IIIa Platelet Receptor...", Circulation, vol 89, no2, 2/94, pp 596 - 603	
		Schultz, " Use of C7E3 Fab in Conjunction With Primary Coronary...", Catherization and Coardiovascular Diagnosis, vol 39, 1996, pp 143 - 148	
		Lincoff, "Platelet Glycoprotein IIb/IIIa Receptor Blocade And ...", New England J. of Med., vol 336, no 24, 6/12/97, pp 1689-1697	
		Gold, "Pharmacodynamic Study of F (ab) ₂ Fragments of ...", J. Clin. Invest., vol 86, 8/90, pp 651 - 659	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.